drug · small molecule
PRV-211
Phase 3updated 5mo agoby Privo Technologies Inc🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 7- drugcisplatin SR3 co-mentions · 3 sources
- drugiCIP3 co-mentions · 3 sources
- drugPRV-1313 co-mentions · 3 sources
- drugcisplatin3 co-mentions · 3 sources
- tagOncology2 co-mentions · 1 sources
- companyVirginia Commonwealth University1 co-mentions · 1 sources
- companyNational Cheng-Kung University Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and mesothelioma and 135 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying PRV-211
- phase3Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase3Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- phase2Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- phase2A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- phase2Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase2A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
News(3)
- Platinum-based chemotherapy in childhood causes mutations that age the liverPlatinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumorsstat · 20d ago
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 4mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that